Table 2.
Dydrogesterone Treatment n = 509 * |
No Dydrogesterone Treatment n = 357 * |
p-Value | |
---|---|---|---|
Anatomical evaluation (Abnormal/Tested) | 4.3 (6/141) | 7.4 (2/27) | 0.616 |
Karyotype (Abnormal/Tested) | - (0/39) | - (0/11) | - |
TSH (Abnormal/Tested) | 10.3 (48/466) | 6.1 (17/279) | 0.063 |
Prolactin (Abnormal/Tested) | 11.1 (26/234) | 8.9 (8/90) | 0.687 |
Glucose (Abnormal/Tested) | 34.4 (33/96) | 31.8 (7/22) | 1.000 |
HbA1C (Abnormal/Tested) | 6.9 (2/29) | - (0/4) | 1.000 |
Anti-thyroid peroxidase (Abnormal/Tested) | 14.1 (26/185) | 9.7 (6/62) | 0.513 |
Antithyroglobulin (Abnormal/Tested) | 7.8 (13/166) | 12.1 (7/58) | 0.421 |
Lupus anticoagulant (LAC) | 2.3 (6/265) | 1.6 (1/63) | 1.000 |
ACL IgG (Abnormal/Tested) |
2.8 (7/250) | 1.0 (1/99) | 0.449 |
ACL IgM (Abnormal/Tested) |
2.0 (5/255) | 1.0 (1/101) | 1.000 |
A.B2 glycoprotein IgG (Abnormal/Tested) |
0.5 (1/219) | 1.2 (1/85) | 0.482 |
A.B2 glycoprotein IgM (Abnormal/Tested) |
1.8 (4/224) | 6.9 (6/87) | 0.032 |
Antinuclear Ab (Abnormal/Tested) |
10.2 (17/167) | 8.1 (6/74) | 0.813 |
Rheumatoid factor (Abnormal/Tested) |
5.5 (11/200) | 8.4 (7/83) | 0.423 |
Protein C (Abnormal/Tested) |
2.9 (5/170) | 3.1 (2/65) | 1.000 |
Protein S (Abnormal/Tested) |
22.2 (6/27) | - (0/11) | 0.154 |
Antithrombin 3 (Abnormal/Tested) |
0.6 (1/165) | 1.6 (1/64) | 0.482 |
Factor V Leiden mutation (Abnormal/Tested) |
9.1 (3/33) | 37.5 (3/8) | 0.048 |
Prothrombin mutation (Abnormal/Tested) |
3.3 (1/30) | - (0/7) | 1.000 |
* Missing values: anatomical evaluation: n = 698; karyotype: n = 816; TSH: n = 121; prolactin: n = 542; glucose: n = 748; HbA1C: n = 833; anti-thyroid peroxidase: n = 619; antithyroglobulin: n = 642; LAC: n = 538; ACL IgG: n = 517; ACL IgM: n = 510; A.B2 glycoprotein IgG: n = 562; A.B2 glycoprotein IgM: n = 555; antinuclear Ab: n = 625; rheumatoid factor: n = 583; protein C: n = 631; protein S: n = 828; antithrombin 3: n = 637; factor V Leiden mutation: n = 825; mutation prothrombin: n = 829.